



Assessment of individual cognitive changes after deep
brain stimulation surgery in Parkinson’s disease using the
Neuropsychological Test Battery Vienna short version
Thomas Foki · Daniela Hitzl · Walter Pirker · Klaus Novak · Gisela Pusswald · Eduard Auff · Johann Lehrner
Received: 25 August 2016 / Accepted: 18 January 2017
© The Author(s) 2017. This article is available at SpringerLink with Open Access.
Summary Long-term therapy of Parkinson’s disease
with L-DOPA is associated with a high risk of de-
veloping motor fluctuations and dyskinesia. Deep
brain stimulation (DBS) of the subthalamic nucleus
(STN) can improve these motor complications. Al-
though the positive effect on motor symptoms has
been proven, postoperative cognitive decline has been
documented. To tackle the impact of DBS on cogni-
tion, 18 DBS patients were compared to 25 best med-
ically treated Parkinson’s patients, 24 patients with
mild cognitive impairment (MCI) and 12 healthy con-
trols using the Neuropsychological Test Battery Vi-
enna short version (NTBV-short) for cognitive out-
come 12 months after the first examination. Reliable
change index methodology was used. Roughly 10% of
DBS patients showed cognitive decline mainly affect-
ing the domains attention and executive functioning
(phonemic fluency). Further research is needed to
identify the mechanisms that lead to improvement
or deterioration of cognitive functions in individual
cases.
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Introduction
Parkinson’s disease (PD) has traditionally been re-
garded as a movement disorder characterized by
bradykinesia, rigidity and tremor. In recent years,
it has been recognized that the clinical spectrum of
PD extends beyond the pure motor syndrome and
includes a plethora of autonomic, sensory, neuropsy-
chiatric and cognitive features. Impaired cognitive
performance in domains such as attention, language,
memory and executive functions has been docu-
mented in a number of studies [1, 2] and PD patients
also have a higher risk of developing dementia [3].
Although sufficient control of motor symptoms can
be attained with pharmacological treatment at the be-
ginning of the disease, barely controllable motor com-
plications develop over the long term. In cases with
refractory motor complications, deep brain stimula-
tion (DBS) offers an alternative to oral drug treatment
and can lead to a marked improvement of these mo-
tor complications and of quality of life [4]. Although
DBS is an established surgical therapy of motor symp-
toms in PD, postoperative cognitive dysfunction has
been reported [5–7]. In general, it was found that
DBS compromises executive functions, especially ver-
bal fluency [5, 8]. Results concerning other neuropsy-
chological tasks show heterogeneous findings. While
some studies found additional worsening in working
memory, attention and memory [8], others described
changes in speed of mental processing, set switching
and phonemic fluency [9].
Reliable change index (RCI) methodology was de-
veloped to take into account variances in test scores
taken at two times [11]. RCI methodology is based
on test-retest reliability (rtt) of tests and is a method
to investigate outcome effects in single patients. The
RCI methodology aims to record changes in results at
two times of measurement without being affected by
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chance. Changes of outcome results due to practice
effects have to be differentiated from changes due to
disease effects or intervention effects. In serial testing
procedures improvement in test performance can be
achieved solely through practice effects. On the other
hand, effects of aging and disease progression may
influence test outcome. Furthermore, effects of ther-
apeutic interventions must be considered. Because
of the neurodegenerative nature of PD, progressive
changes in neuropsychological testing in individual
cases over time have to be expected. Additionally,
changes due to clinical and therapeutic effects must
be considered, e. g. medication effects, related fluctu-
ations and depressive symptoms. To take these factors
into account, RCI methodology has been developed.
There are several reports available which describe RCI
methodology in PD [10, 11]. Recent studies have in-
vestigated the effect of DBS on cognition in single pa-
tients using RCI methodology. In general, significant
cognitive deterioration was found only in a few sub-
thalamic nucleus (STN)-DBS patients suggesting that
neuropsychological evaluations may identify possible
mild cognitive changes following surgery [12–19]. An
open question is whether cognitive changes in after
DBS in PD patients using RCI methodology is compa-
rable to changes in healthy age matched controls con-
trolling for aging effects and other clinical populations
such as mild cognitive impairment (MCI) controlling
for neurodegenerative effects.
The purpose of this study was to investigate the
impact of DBS on cognition using RCI methodology.
We wanted to tackle changes of neurocognitive func-
tioning related to treatment in PD patients who un-
derwent surgery compared to best medically treated
PD patients. Furthermore, an important goal was to
study RCI methodology in healthy controls and pa-
tients with MCI and compare it to PD patients with
surgery.
Patients and methods
The current data are part of a larger research project,
the Vienna Mild Cognitive Impairment and Cogni-
tive Decline in Parkinson’s Disease study (VMCI-CD-
PD study). The VMCI-CD-PD study is a prospec-
tive cohort study including consecutive, community-
dwelling PD patients who attend the movement dis-
order clinic for assessment of parkinsonism. The
study protocol was in accordance with the Helsinki
Declaration and approved by the ethical committee
of the Medical University of Vienna.
All PD patients underwent clinical examination and
neuropsychological testing. The clinical assessment
encompassed a complete medical history, a detailed
history of PD, which was obtained using a standard-
ized interview, and a complete neurological exam-
ination including the motor section of the Unified
Parkinson’s Disease Rating Scale (UPDRS-III) [20] and
the modified Hoehn and Yahr scale [21]. Clinical ex-
amination and neuropsychological testing were per-
formed during the “on” state. Patients who had never
undergone computed tomography (CT) or magnetic
resonance imaging (MRI) during the course of PD
and patients showing clinical features incompatible
with previous imaging results were referred to struc-
tural imaging. Both neuroimaging and clinical fea-
tures were used to determine significant cerebrovas-
cular disease or other comorbid conditions with a po-
tential impact on cognitive outcomes.
Inclusion and exclusion criteria were similar to
those used in other studies. All PD patients had to
fulfill UK Parkinson’s Disease Society Brain Bank cri-
teria [22] for probable PD. Inclusion and exclusion
criteria were specified as follows: PD-DBS patients
suffered from PD for at least 5 years with a pos-
itive response to L-DOPA treatment. All PD-DBS
patients suffered from motor complications (fluctu-
ations with or without dyskinesia) refractory to oral
drug treatment or treatment-resistant PD tremor. Pa-
tients with secondary or atypical parkinsonism were
excluded. Severe cognitive impairments, such as de-
mentia and uncontrolled psychiatric disorders also
represented exclusion criteria. Comorbidities and
structural brain lesions that would interfere with the
surgical procedure were ruled out. Controls and pa-
tients were excluded from the study if any of the
following conditions applied: (a) evidence of a past
stroke as determined by neuroradiological and clin-
ical examination, (b) history of severe head injury,
(c) current psychiatric diagnosis according to ICD-10
with the exception of patients with (sub)depressive
symptoms, (d) any medical condition that can lead
to cognitive deterioration including renal, respiratory,
cardiac and hepatic disease, or (e) a diagnosis of de-
mentia according to DSM IV criteria [23]. Patients
were assessed on their regular medication and were
required to have a mini-mental state examination
(MMSE) score of ≥ 26.
All participants were subjected to the short version
of the Neuropsychological Test battery Vienna (NTBV)
for assessment of their neurocognitive functions. The
NTBV-short assesses several cognitive domains in-
cluding attention, executive functioning, language
and memory domains with corresponding domain
z scores [24]. In addition, a total z-score across all
tests was computed [25]. The “Alters-Konzentrations-
Test” (AKT) [26] and the symbol counting task from
the cerebral insufficiency test (CI) [27] were used to
assess attention. Executive functions were investi-
gated using the Trail Making Test A, the Maze Test
from the NAI test battery [28], and the interference
test from the CI [27]. Naming as many words be-
ginning with the letter f that came to mind within
1 min was used to tap lexical verbal fluency [29].
In order to test language functions, we used a ver-
bal fluency task naming as many animals [29], and
a confrontation naming task (Boston Naming Test)
[30]. Episodic memory was tested using the Verbal
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Selective Reminding Test (VSRT) with the subtests
of immediate recall, total recall, delayed recall and
recognition [31]. After the completion of the tests,
the cognitive status was determined according to
the Petersen criteria [32], and the cut-off score used
was 1.5 standard deviations below age and education
corrected norms using a normative sample of cogni-
tively healthy controls. For this purpose, the flexible
Generalized Additive Models for Location, Scale and
Shape (GAMLSS) model class was used [33]. The
NTBV was performed two times, the second testing
was performed 1 year after the first.
The study included 79 participants subdivided into
4 groups. Patients with PD were divided into a PD-
DBS group (DBS plus best medical treatment) and
a PD-BMT group (best medical treatment only). The
DBS group underwent deep brain stimulation after
the first testing. Patients received bilateral magnetic
resonance (MR)-based, stereotactic DBS surgery. The
optimum electrode position within the STN was as-
sessed intraoperatively in the awake patient, applying
macrostimulation to test for motor improvement and
side effects. A small minority of PD patients with anx-
iety disorder underwent DBS surgery under general
anesthesia. PostoperativeMR imaging (MRI) was used
to exclude perioperative structural lesions and to reas-
sure correct electrode position. Starting with standard
DBS parameters (60 μs impulse duration at 130Hz),
the voltage was gradually increased over 1–2 weeks
and stimulation parameters adjusted individually. In
parallel, dopaminergic therapy was decreased gradu-
ally [34, 35]. Community-dwelling patients complain-
ing of cognitive problems who came to the memory
outpatient clinic for assessment of a possible cogni-
tive disorder were included in the study. Mild cogni-
tive impairment (MCI) was defined according to the
Petersen criteria [32].
The healthy control group consisted of patients
without PD and cognitive impairments. Great care
was taken to enrol a sufficient number of cogni-
tively healthy control subjects living independently at
home. Control subjects were recruited by means of
advertisements and underwent a rigorous screening
evaluation using a standardized clinical interview and
cognitive screening. Imaging procedures, neurologi-











Age 62.9 ± 7.7 65.1 ± 5.7 63.1 ± 7.4 62.9 ± 6.5 60.0 ± 10.2
Education 10.1 ± 2.3 9.9 ± 2.3 10.0 ± 2.3 10.4 ± 2.35 10.1 ± 2.3
Sex (m/w) 37/42 3/9 14/10 14/11 6/12
MMSE 28.3 ± 1.3 28.8 ± 0.8 28.1 ± 1.2 28.4 ± 1.2 28.0 ± 1.6
WST 103.9 ± 10.0 103.0 ± 7.5 104.5 ± 9.9 103.2 ± 10.6 106.1 ± 12.1
BDI-II 10.2 ± 6.0 10.7 ± 5.8 10.3 ± 5.4 9.3 ± 6.1 11.7 ± 7.3
UPDRS motor score – – – 28.4 ± 12.7 25.1 ± 10.5
Hoehn & Yahr scale – – – 3.68 ± 1.9 3.8 ± 1.0
MMSE mini mental state examination, WST “Wortschatz Test”, BDI-II Beck-Depression Inventory, UPDRS Unified Parkinson’s Disease Rating Scale
cal examination, standard laboratory blood tests and
informant reports were not included in the evaluation.
They were assessed as being in good health. Criteria
for healthy function were identified as being similar
to those in the Mayo research studies [36]: (a) no
active neurological or psychiatric disease, (b) no psy-
chotropic medications, and (c) the subjects may have
medical disorders but neither they nor their treatment
compromises cognitive function. Cognitive status was
given special attention and cognitively healthy con-
trol subjects were screened for intact cognition. They
were required to have an MMSE score greater than or
equal to 27 and a MOCA score greater than or equal
to 26 adjusted for education. Control subjects did not
overtly complain about cognitive problems.
All four patient groups were matched for age, gen-
der, MMSE status [37], verbal intelligence (WST)
[38] and depressive symptoms (BDI-II) [39]. Using
Kruskal-Wallis analyses no statistical group differ-
ences were found (all p > 0.3). Demographic and
clinical data are shown in Table 1.
Statistical analyses
Based on the mean test z-scores for each cogni-
tive domain, standard deviations were calculated for
each domain separated by group [10, 11]. Mean
test z-scores and standard deviations were used for
calculating the RCI as follows:
RC I = ((X2−X1)− (M2−M1)) ·SED
The difference of (X2-X1) characterizes the individ-
ual test scores of a participant at the two test sessions
over time. M2 and M1 represent the mean z-scores of
the group the participant is compared to. The calcu-
lation of the standard error of difference (SED) uses
the standard deviation and rtt of the specific compar-
ison group. The standard deviation is taken from the
first test session. The rtt coefficient of a given test is
calculated by using test scores of the first test session
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SE M = SD
√
(1− rt t )
This formula is based on Chelune et al. [11] and
a significant change can be assumed at a change of
±1.64 (p = 0.05). Based on this a confidence interval is
calculated to determine a minimum and a maximum
limit which represent significant changes.
In order to ensure reproducibility for future studies,
the calculations are shown here using a case example.
A patient taken from the DBS group is compared to
the PD-BMT group for the memory domain. All scores
have already been transformed into z-scores. The cal-
culation process is divided into two steps. At first, cal-
culation of the confidence interval using mean score
and standard deviation of the PD-BMT group is per-
formed for both test sessions. Mean score of themem-
ory domain at first testing session was –0.188 with
a standard deviation of 0.538 for the PD group. Mean
score of the memory domain at the second testing
session was –0.472 with a standard deviation of 0.671
for the PD-BMT group. The rtt coefficient (rtt = 0.649)
results from the correlation of the test scores across
time for the PD group. The formula for the standard
error of measurement (SEM) is derived by including
the test-retest correlation coefficient and standard de-
viation from the PD-BMT group.
SE M = 0,538 ·
√
(1−0,649)= 0,319





According to Chelune et al. [11] a deviation of ±1.64
can be assumed as statistically significant.
C I = 1,64 ·0,451= 0,74
The upper and lower scores of the confidence in-
terval are serving as limiting values for defining sta-
tistical significance. After subtracting the second and
the first mean score (M2–M1), the confidence inter-
val is added or subtracted. Difference of mean scores
(DM): M2–M1 = –0.284. Limiting value deterioration:
–CI + DM = –0.74 – 0.284 = –1.024. Limiting value im-
provement: CI + DM = 0.74 – 0.284 = 0.456. A patient’s
RCI has to be higher or lower than the limiting values
in order to detect a statistically significant change be-
tween the first and second testing. The scores of the
reliability coefficient, standard error of the mean and
SED are calculated like shown above. For the memory
domain the figures are as follows: rtt = 0.577; SEM =
0.621; SED = 0.878; M1 = –0.456; M2 = –0.635.
The patient chosen for the illustrative example has
achieved a z-score of –2.4 (X1) in the first and –1.9
(X2) in the second testing in the memory domain.
The mean scores of the group and the individual test
scores are put in the formula for calculating the reli-
able change index: RCI = (((–1.9) – (–2.4)) – ((–0.635) –
(–0.456)))·0.878 = 0.596. This results in a RCI score of
0.596 for this patient. This value is compared with the
limiting values calculated above. The upper limiting
value of 0.456 is surpassed; therefore, an improvement
of memory ability in this patient in comparison to the
Parkinson’s disease group has been detected.
Results
In order to determine the individual performance
using RCI methodology, RCI calculations were per-
formed for each participant in each group for every
domain. The scores of the reliability coefficient, SEM,
SED and the limiting values for improvement and
deterioration as calculated for the PD-MBT group,
healthy control group and MCI group and are shown
in Table 2. The table shows the results for the RCI
analysis comparing the DBS group to the calculated
limiting values of the PD-BMT group, the control
group and the MCI group.
The results of the comparison between the PD-
DBS group and all other groups are displayed in Ta-
ble 3. The only significant deterioration detected can
be found in the domain executive functioning (phone-
mic fluency) with 11.1% of patients showing a signif-
icant deterioration. The comparison of the PD-DBS
group with the healthy control group revealed signif-
icant deteriorations in the domain attention as well
as in the domain of executive functioning (phone-
mic fluency) in 11.1% of patients. No other domain
showed significant deteriorations. When comparing
MCI patients to DBS patients no significant deterio-
rations have been detected.
Discussion
Deep brain stimulation has evolved to become an im-
portant therapeutic option in the treatment of PD [4].
As DBS is a lifelong treatment, it is important to eval-
uate possible side effects, particularly cognitive de-
cline after DBS treatment. The gold standard to evalu-
ate cognitive outcome is randomized controlled stud-
ies; however, randomized controlled study methodol-
ogy is not suitable for assessing cognitive outcome in
a single patient in the clinical setting. In order to pre-
dict cognitive outcome in a single patient in clinical
settings, RCI methodology has been developed [11].
Our study investigated cognitive outcome after DBS in
comparison to three groups, namely a best medically
treated PD group (PD-BMT group), a healthy control
group without cognitive impairment (healthy control
group) and a group consisting of patients having mild
cognitive impairment (MCI group). All groups were
matched in terms of age, education, IQ, MMSE sta-
tus and depressive symptoms. When compared to
a PD-BMT group we found that approximately 10%
of patients showed cognitive deterioration 1 year after
DBS. The cognitive domain only affected was execu-
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Attention –0.7 ± 1.4 –1.0 ± 1.2 0.7 0.7 0.9 –1.8 1.1
Language –0.5 ± 0.7 –0.5 ± 0.8 0.6 0.5 0.6 –1.1 1.0
Executive function (phonemic flu-
ency)
–0.5 ± 1.0 –0.4 ± 1.1 0.7 0.5 0.7 –1.1 1.3
Memory –0.2 ± 0.5 –0.5 ± 0.6 0.6 0.3 0.5 –1.0 0.4
Executive function (nonverbal plan-
ning)
–0.8 ± 1.1 –0.6 ± 1.0 0.6 0.7 1.0 –1.5 1.7
Total NTBV short –0.5 ± 0.7 –0.6 ± 0.6 0.8 0.3 0.5 –0.8 0.6
Control group
Attention 0.8 ± 1.2 0.2 ± 0.9 0.3 0.9 1.3 –2.6 1.6
Language –0.1 ± 0.5 –0.2 ± 0.6 0.5 0.3 0.5 –0.8 1.1
Executive function (phonemic flu-
ency)
0.1 ± 0.9 0.2 ± 1.1 0.6 0.6 0.9 –1.2 1.5
Memory –0.1 ± 0.7 –0.3 ± 0.5 0.2 0.6 0.8 –1.7 1.0
Executive function (nonverbal plan-
ning)
0.6 ± 0.8 0.7 ± 0.7 0.5 0.5 0.8 –1.0 1.4
Total NTBV short 0.3 ± 0.5 0.2 ± 0.5 0.5 0.3 0.4 –0.7 0.6
MCI group
Attention –0.2 ± 1.3 –0.1 ± 1.3 0.6 0.7 1.0 –1.6 1.7
Language –0.6 ± 0.8 –0.7 ± 0.9 0.6 0.5 0.6 –1.1 0.9
Executive function (phonemic flu-
ency)
–0.6 ± 1.2 –0.5 ± 1.0 0.6 0.8 1.1 –1.8 1.8
Memory –0.5 ± 0.9 –1.0 ± 1.1 0.6 0.5 0.7 –1.6 0.6
Executive function (nonverbal plan-
ning)
0.1 ± 1.1 –0.1 ± 1.2 0.7 0.6 0.8 –1.5 1.0
Total NTBV short –0.3 ± 0.7 –0.4 ± 0.8 0.6 0.4 0.6 –1.0 0.7
rtt test-retest reliability, SEM standard error of measurement, SED standard error of difference, PD-BMT Parkinson’s Disease best medically treated, MCI Mild
cognitive impairment, NTBV Neuropsychological Test Battery Vienna
tive functioning, namely phonemic fluency. All other
domains showed no significant cognitive deteriora-
tion after DBS compared to a PD-BMT group. It is
noteworthy that significant deterioration of a partic-
ular cognitive function only affected a small minority
of our patient cohort.
Several previous studies found changes in phone-
mic fluency, mostly deteriorations [40–42]. The de-
cline in phonemic fluency represents the most com-
mon neurocognitive change after DBS. It seems that
DBS has a negative impact on this executive function
at least in some patients. Studies on other neurosur-
gical interventions such as pallidotomy and pallidus
pars interna (GPi) stimulation also reported deteriora-
tion in phonemic fluency [43–45] although to a lesser
degree [7]. The deterioration of phonemic fluency
may therefore be a side effect of frontal lobe trajec-
tory use to access the basal ganglia [40].
We found no significant changes for the domain of
language. Prior studies have shown positive changes
after surgery on different levels of language and
speech [46, 47]. These improvements have not been
found in all studies and Funkiewiez et al. even found
diminished verbal abilities [48]. Impairment in lan-
guage may occur immediately after surgery caused
by interference with neural networks. In long-term
follow-up examinations no further deterioration was
found after 3 years [49].
The memory domain showed no decline in our
study. The fact that DBS may cause enhancement of
memory abilities has been shown in previous studies
[50, 51]. Direct and indirect projections of the STN
to the dorsal striatum may be implicated in mem-
ory functions. Memory improvements after DBS may
be explained by an improved striatal transmission of
dopamine [40–42].
The results of our study corroborate previous stud-
ies investigating the cognitive outcome after DBS in
PD using RCI methodology. As in our study, earlier
studies also found low prevalence of cognitive decline
in single cognitive domains [12–19].
Several authors discussed the influence on cogni-
tive results by the neurosurgical intervention itself. As
cerebral tissue may be aggrieved during surgery, path-
ways may be impaired without interference caused
by stimulation. Prior studies also implied that post-
operative outcome is affected by factors other than
surgery and stimulation. Potential negative predispo-
sitions are high age when receiving stimulation and
a low number of years of education [43–45].
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Table 3 Resultsof individual comparisonbetweenPD-BMTgroup–PD-DBSgroup, control group–PD-DBSgroupandMCI
group–PD-DBSgroup
N deteriorated % deteriorated N no change % no change N improved % improved
PD-BMT – PD-DBS
Attention 0 0.0 18 100 0 0.0
Language 0 0.0 18 100 0 0.0
Executive function (phonemic fluency) 2 11.1 14 77.7 2 11.1
Memory 0 0.0 15 83.3 3 16.6
Executive function (nonverbal planning) 0 0.0 18 100 0 0.0
Total NTBV short 0 0.0 18 100 0 0.0
Control – PD-DBS
Attention 2 11.1 16 88.8 0 0.0
Language 0 0.0 18 100 0 0.0
Executive function (phonemic fluency) 2 11.1 14 77.7 2 11.1
Memory 0 0.0 17 94.4 1 5.5
Executive function (nonverbal planning) 0 0.0 18 100 0 0.0
Total NTBV short 0 0.0 18 100 0 0.0
MCI – PD-DBS
Attention 0 0.0 18 100 0 0.0
Language 0 0.0 18 100 0 0.0
Executive function (phonemic fluency) 0 0.0 17 94.4 1 5.5
Memory 0 0.0 17 94.4 1 5.5
Executive function (Nonverbal planning) 0 0.0 18 100 0 0.0
Total NTBV short 0 0.0 18 100 0 0.0
PD-DBS Parkinson’s disease deep brain stimulation, PD-BMT Parkinson’s disease best medically treated, MCI Mild cognitive impairment, NTBV Neuropsycho-
logical Test Battery Vienna
An important task of the present study was to com-
pare DBS patients to a healthy control group and
a group with MCI controlling for aging effects and
effects of cognitive deterioration besides PD. When
compared to the healthy control groupwe found a sig-
nificant decline in attention in roughly 10% of DBS
patients showing that there is a mild decline in the
domain of attention above that seen in normal aging.
Comparing PD-DBS patients and MCI patients no sig-
nificant cognitive decline could be detected indicating
that the DBS procedure did not produce significant
cognitive changes above that seen in patients with
mild cognitive impairment. To our knowledge, this is
the first study to report such findings.
As with every other study this study has strengths
and limitations. Using RCI methodology is a strength
enabling direct comparison of different groups in sin-
gle patient analysis. The PD patients and controls
groups were closely matched in terms of age, edu-
cation, IQ, MMSE status and depressive symptoms.
A limitation is certainly the partially small group sizes.
Another limitation is that the findings may not be gen-
eralized to all PD patients because our patients were
recruited in a university-based specialized clinic for
movement disorders.
Assessment of intraindividual cognitive stability
and change is of considerable importance for the
diagnosis of incident dementia and evaluation of
treatment effectiveness in several clinical populations
e. g. including PD and Alzheimer’s Disease (AD). We
provide rtt reliability scores, expected practice effects
and practice-corrected reliable change indices for the
NTBV. Our data may be useful to researchers and
clinicians interested in determining the statistical sig-
nificance of change in cognitive test performance in
patients with PD over a time interval of 12 months.
Although some parts of cognition showed improve-
ment as well as deterioration, most PD patients sub-
jectively do not suffer from these changes in terms
of activities of daily living [48]. In general, DBS rep-
resents a safe and effective PD therapy when motor
complications begin to decrease quality of life. Side ef-
fects of the treatment are often slight, intermittent and
well-tolerated by patients. The advantages of the ther-
apy are usually predominant. Future studies should
also assess the impact of DBS on individual patient
psychosocial outcome.
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